Royalty Pharma (RPRX) Change in Acquisitions & Divestments (2019 - 2026)

Royalty Pharma has disclosed Change in Acquisitions & Divestments across 8 years of filings, most recently posting $4.3 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $4.3 million, down 65.68% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.3 million (down 126.72% YoY), and the FY2024 annual result was $19.8 million, down 18.88% from the prior year.
• Change in Acquisitions & Divestments came in at $4.3 million for Q1 2026 at Royalty Pharma, up from -$18.3 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $645.5 million in Q3 2022 to a low of -$134.7 million in Q4 2022.
• The 5-year median for Change in Acquisitions & Divestments is $3.6 million (2024), against an average of $36.9 million.
• Peak annual rise in Change in Acquisitions & Divestments reached 774.03% in 2025, while the deepest fall reached 245.77% in 2025.
• Royalty Pharma's Change in Acquisitions & Divestments stood at -$134.7 million in 2022, then soared by 118.11% to $24.4 million in 2023, then slumped by 48.4% to $12.6 million in 2024, then slumped by 245.77% to -$18.3 million in 2025, then jumped by 123.55% to $4.3 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $4.3 million (Q1 2026), -$18.3 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.